Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
AMGN logo AMGN
Upturn stock ratingUpturn stock rating
AMGN logo

Amgen Inc (AMGN)

Upturn stock ratingUpturn stock rating
$278.4
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

04/22/2025: AMGN (3-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Analysis of Past Performance

Type Stock
Historic Profit 22.52%
Avg. Invested days 43
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 04/22/2025

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 150.99B USD
Price to earnings Ratio 37.15
1Y Target Price 314.62
Price to earnings Ratio 37.15
1Y Target Price 314.62
Volume (30-day avg) 3212499
Beta 0.58
52 Weeks Range 251.27 - 338.98
Updated Date 04/25/2025
52 Weeks Range 251.27 - 338.98
Updated Date 04/25/2025
Dividends yield (FY) 3.40%
Basic EPS (TTM) 7.56

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-05-01
When After Market
Estimate -
Actual -

Profitability

Profit Margin 12.24%
Operating Margin (TTM) 51.81%

Management Effectiveness

Return on Assets (TTM) 6.4%
Return on Equity (TTM) 67.55%

Valuation

Trailing PE 37.15
Forward PE 13.46
Enterprise Value 198994636192
Price to Sales(TTM) 4.52
Enterprise Value 198994636192
Price to Sales(TTM) 4.52
Enterprise Value to Revenue 5.95
Enterprise Value to EBITDA 14.9
Shares Outstanding 537204992
Shares Floating 535840442
Shares Outstanding 537204992
Shares Floating 535840442
Percent Insiders 0.22
Percent Institutions 81.96

Analyst Ratings

Rating 3.59
Target Price 319.35
Buy 4
Strong Buy 10
Buy 4
Strong Buy 10
Hold 15
Sell 1
Strong Sell 2
Strong Sell 2

ai summary icon Upturn AI SWOT

Amgen Inc

stock logo

Company Overview

overview logo History and Background

Amgen Inc. was founded in 1980 as Applied Molecular Genetics. A significant milestone was the FDA approval of Epogen in 1989. It has evolved into a global biotechnology leader.

business area logo Core Business Areas

  • General Medicine: Focuses on therapies for cardiovascular disease, bone health, and other general medical conditions.
  • Oncology: Develops and markets therapies for various types of cancer.
  • Inflammation: Focuses on therapies for inflammatory diseases.
  • Hematology: Focuses on therapies for various blood diseases and disorders

leadership logo Leadership and Structure

Robert A. Bradway is the Chairman and CEO. The company operates with a functional organizational structure, divided into research, development, and commercial operations.

Top Products and Market Share

overview logo Key Offerings

  • Enbrel: A TNF blocker used to treat autoimmune diseases like rheumatoid arthritis. Faces competition from biosimilars. Revenue 2023: $6.4 billion. Competitors: AbbVie's Humira, Johnson & Johnson's Remicade.
  • Prolia/Xgeva: Prolia treats osteoporosis; Xgeva prevents skeletal-related events in cancer. Revenue 2023: $4.1 billion. Competitors: Novartis's Reclast, Merck's Fosamax.
  • Neulasta/Neupogen: Used to stimulate white blood cell production in cancer patients undergoing chemotherapy. Faces competition from biosimilars. Revenue 2023: $1.7 billion. Competitors: Sandoz's Zarxio, Mylan's Fulphila.
  • Otezla: An oral treatment for psoriasis and psoriatic arthritis. Revenue 2023: $2.5 billion. Competitors: Celgene's (now Bristol Myers Squibb) Apremilast, Novartis's Cosentyx.

Market Dynamics

industry overview logo Industry Overview

The biotechnology industry is characterized by high R&D spending, complex regulatory pathways, and intense competition. Patent protection and biosimilar challenges are critical factors.

Positioning

Amgen is a leading biotechnology company with a strong portfolio of established products and a robust pipeline of innovative therapies. It has competitive advantages in manufacturing and commercialization.

Total Addressable Market (TAM)

The global pharmaceutical market is estimated to be worth over $1.4 trillion. Amgen addresses a significant portion of this market, including oncology, inflammation, bone health, and cardiovascular disease.

Upturn SWOT Analysis

Strengths

  • Strong product portfolio
  • Robust pipeline of new drugs
  • Established manufacturing capabilities
  • Strong financial performance
  • Global presence

Weaknesses

  • Reliance on key products
  • Exposure to biosimilar competition
  • High R&D expenses
  • Patent expirations

Opportunities

  • Expansion into new therapeutic areas
  • Strategic acquisitions and partnerships
  • Growth in emerging markets
  • Development of innovative therapies
  • Leveraging digital health technologies

Threats

  • Increasing competition from biosimilars
  • Pricing pressures and healthcare reforms
  • Regulatory hurdles
  • Patent challenges
  • Economic downturns

Competitors and Market Share

competitor logo Key Competitors

  • JNJ
  • MRK
  • PFE
  • ABBV
  • BMY

Competitive Landscape

Amgen faces competition from established pharmaceutical companies and emerging biotechnology firms. Its strengths include its manufacturing capabilities and global presence. Its weaknesses include its reliance on key products and exposure to biosimilar competition.

Major Acquisitions

Horizon Therapeutics

  • Year: 2023
  • Acquisition Price (USD millions): 27800
  • Strategic Rationale: Expands Amgen's portfolio in rare diseases and inflammation.

Growth Trajectory and Initiatives

Historical Growth: Amgen has experienced consistent revenue and earnings growth over the past decade, driven by its strong product portfolio and strategic acquisitions.

Future Projections: Analysts project continued revenue and earnings growth for Amgen in the coming years, driven by its pipeline and strategic initiatives.

Recent Initiatives: Recent initiatives include acquisitions of Horizon Therapeutics, investments in new manufacturing facilities, and development of innovative therapies.

Summary

Amgen is a strong biotechnology company with a diverse product portfolio and a robust pipeline. Its established manufacturing capabilities and global presence are significant advantages. However, Amgen faces challenges from biosimilar competition and pricing pressures and must continue to innovate and pursue strategic acquisitions to drive future growth.

Similar Companies

ABBVratingrating

AbbVie Inc

$176.9
Large-Cap Stock
0%
PASS

ABBVratingrating

AbbVie Inc

$176.9
Large-Cap Stock
0%
PASS

BMYratingrating

Bristol-Myers Squibb Company

$49.82
Large-Cap Stock
0%
PASS

BMYratingrating

Bristol-Myers Squibb Company

$49.82
Large-Cap Stock
0%
PASS

GILDratingrating

Gilead Sciences Inc

$105.51
Large-Cap Stock
0%
PASS

GILDratingrating

Gilead Sciences Inc

$105.51
Large-Cap Stock
0%
PASS

JNJratingrating

Johnson & Johnson

$157.75
Large-Cap Stock
0%
PASS

JNJratingrating

Johnson & Johnson

$157.75
Large-Cap Stock
0%
PASS

LLYratingrating

Eli Lilly and Company

$827.54
Large-Cap Stock
0%
PASS

LLYratingrating

Eli Lilly and Company

$827.54
Large-Cap Stock
0%
PASS

MRKratingrating

Merck & Company Inc

$77.85
Large-Cap Stock
0%
PASS

MRKratingrating

Merck & Company Inc

$77.85
Large-Cap Stock
0%
PASS

PFEratingrating

Pfizer Inc

$22.53
Large-Cap Stock
0%
PASS

PFEratingrating

Pfizer Inc

$22.53
Large-Cap Stock
0%
PASS

Sources and Disclaimers

Data Sources:

  • Amgen Investor Relations
  • SEC Filings
  • Analyst Reports
  • Company Press Releases
  • Third Party Market Research

Disclaimers:

The data and analysis provided are for informational purposes only and should not be considered investment advice. Market conditions and company performance are subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Amgen Inc

Exchange NASDAQ
Headquaters Thousand Oaks, CA, United States
IPO Launch date 1983-06-17
Chairman, CEO & President Mr. Robert A. Bradway
Sector Healthcare
Industry Drug Manufacturers - General
Full time employees 28000
Full time employees 28000

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!